Eye-based glucose monitor developer expands series A
This article was originally published in Clinica
Freedom Meditech, a developer of noninvasive ophthalmic devices for monitoring glucose levels in diabetics, has expanded its series A financing after raising an additional round of funds. The amount invested in the second tranche was not disclosed. Participants in the round include existing shareholder JumpStart Ventures and various individual investors. Additionally, the company welcomed new investor Catherine Stiefel, a long-time director of Stiefel Laboratories and now also a director on Freedom's board. Cleveland, Ohio-based Freedom is developing a handheld device that is designed to provide immediate glucose level readings by shining a light in the eye.
You may also be interested in...
Minimally invasive glaucoma surgery specialist Glaukos saw its stock leap 40% in the wake of a worldwide recall by much bigger rival Alcon of its CyPass microstent.
Roland Diggelmann will end his decade-long career at Roche Diagnostics at the end of September. The business's head of EMEA Michael Heuer will take Diggelmann's place while the search is on for his replacement.
Philips has added a new pulse oximetry platform to its patient monitoring portfolio, with the acquisition of Xhale Assurance.